Nutr Res Pract.  2019 Oct;13(5):393-398. 10.4162/nrp.2019.13.5.393.

Tea consumption is associated with a reduced risk of coronary heart disease in female but not male populations in Guangzhou, China

• Chen Y
• Ye Y
• Zhang Z
• Zhang C
• Chen M
• Pang J
• Zhou S
• Xiang Q

• KMID: 2464118
• DOI: http://doi.org/10.4162/nrp.2019.13.5.393

Abstract

BACKGROUND/OBJECTIVES
The association between tea consumption and risk of coronary heart disease (CHD) remains controversial. This study aimed to determine whether tea consumption has an effect on CHD risk in Chinese adults.
SUBJECTS/METHODS
In this hospital-based case-control study, 267 cases of CHD and 235 non-CHD controls were enrolled. Blood samples from all cases were examined. Cardiac function indices (left ventricular ejection fraction, left ventricular end-diastolic dimension, lactate dehydrogenase, and creatine kinase of the muscle or brain type), blood lipid index (high-density lipoprotein cholesterol), and blood coagulation function indices (fibrinogen and activated partial thromboplastin time) were recorded. Tea consumption of study participants was assessed by a specifically designed questionnaire. The baseline characteristics of the study populations were recorded, and CHD-related biomarkers were detected. Differences in baseline characteristics of the study participants were examined using t-tests for continuous variables and chi-squared tests for categorical variables. Unconditional logistic regression was used to measure the association between tea and CHD.
RESULTS
There were significant differences in cardiac function indices, blood lipid index, and blood coagulation indices between CHD cases and controls (P < 0.05). We found tea consumption reduced CHD risk in female participants (adjusted odds ratio (OR) = 0.484, 95% CI: 0.242-0.968, P = 0.0403). Regarding the type of tea consumed, the risk of CHD was reduced in women who drank partially fermented tea (adjusted OR = 0.210, 95% CI: 0.084-0.522, P = 0.0008). Analytic results for the amount of tea consumed per unit time showed CHD risk was reduced in women who consumed 1-2 cups of tea per day (adjusted OR = 0.291, 95% CI: 0.131-0.643, P = 0.0023). A tea-drinking frequency of > 6 days/week was beneficial for CHD prevention (adjusted OR = 0.183, 95% CI: 0.049-0.679, P = 0.0112). When analyzed according to the duration of tea consumption, the risk of CHD was reduced in participants who had been drinking tea for 10-20 years (adjusted OR = 0.360, 95% CI: 0.137-0.946, P = 0.0382).
CONCLUSIONS
Tea consumption is associated with a reduced risk of CHD in female but not male populations in Guangzhou.

Keyword

Tea consumption; coronary heart disease risk; coronary heart disease-related biomarker

MeSH Terms

Adult
Asian Continental Ancestry Group
Biomarkers
Blood Coagulation
Brain
Case-Control Studies
China*
Coronary Disease*
Creatine Kinase
Drinking
Female*
Humans
L-Lactate Dehydrogenase
Lipoproteins
Logistic Models
Male*
Odds Ratio
Stroke Volume
Tea*
Thromboplastin
Biomarkers
Creatine Kinase
L-Lactate Dehydrogenase
Lipoproteins
Tea
Thromboplastin

Reference

1. Chatterjee P, Chandra S, Dey P, Bhattacharya S. Evaluation of anti-inflammatory effects of green tea and black tea: a comparative in vitro study. J Adv Pharm Technol Res. 2012; 3:136–138.

2. Subramaniam P, Eswara U, Maheshwar Reddy KR. Effect of different types of tea on Streptococcus mutans: an in vitro study. Indian J Dent Res. 2012; 23:43–48.

3. Zhang C, Qin YY, Wei X, Yu FF, Zhou YH, He J. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol. 2015; 30:103–113.

4. de Koning Gans JM, Uiterwaal CS, van der Schouw YT, Boer JM, Grobbee DE, Verschuren WM, Beulens JW. Tea and coffee consumption and cardiovascular morbidity and mortality. Arterioscler Thromb Vasc Biol. 2010; 30:1665–1671.

5. Grassi D, Draijer R, Schalkwijk C, Desideri G, D'Angeli A, Francavilla S, Mulder T, Ferri C. Black tea increases circulating endothelial progenitor cells and improves flow mediated dilatation counteracting deleterious effects from a fat load in hypertensive patients: a randomized controlled study. Nutrients. 2016; 8:E727.

6. Hibi M, Takase H, Iwasaki M, Osaki N, Katsuragi Y. Efficacy of tea catechin-rich beverages to reduce abdominal adiposity and metabolic syndrome risks in obese and overweight subjects: a pooled analysis of 6 human trials. Nutr Res. 2018; 55:1–10.

7. Miyazaki R, Kotani K, Ayabe M, Tsuzaki K, Shimada J, Sakane N, Takase H, Ichikawa H, Yonei Y, Ishii K. Minor effects of green tea catechin supplementation on cardiovascular risk markers in active older people: a randomized controlled trial. Geriatr Gerontol Int. 2013; 13:622–629.

8. Yan Y, Sui X, Yao B, Lavie CJ, Blair SN. Is there a dose-response relationship between tea consumption and all-cause, CVD, and cancer mortality? J Am Coll Nutr. 2017; 36:281–286.

9. Liu J, Liu S, Zhou H, Hanson T, Yang L, Chen Z, Zhou M. Association of green tea consumption with mortality from all-cause, cardiovascular disease and cancer in a Chinese cohort of 165,000 adult men. Eur J Epidemiol. 2016; 31:853–865.

10. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol. 2001; 154:495–503.

11. Li X, Yu C, Guo Y, Bian Z, Si J, Yang L, Chen Y, Ren X, Jiang G, Chen J, Chen Z, Lv J, Li L. China Kadoorie Biobank Collaborative Group. Tea consumption and risk of ischaemic heart disease. Heart. 2017; 103:783–789.

12. Chen XQ, Wang XB, Guan RF, Tu J, Gong ZH, Zheng N, Yang JH, Zhang YY, Ying MM. Blood anticoagulation and antiplatelet activity of green tea (−)-epigallocatechin (EGC) in mice. Food Funct. 2013; 4:1521–1525.

13. Arts IC, Hollman PC, Feskens EJ, Bueno de Mesquita HB, Kromhout D. Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. Am J Clin Nutr. 2001; 74:227–232.

14. Samavat H, Newman AR, Wang R, Yuan JM, Wu AH, Kurzer MS. Effects of green tea catechin extract on serum lipids in postmenopausal women: a randomized, placebo-controlled clinical trial. Am J Clin Nutr. 2016; 104:1671–1682.

15. Huang LH, Liu CY, Wang LY, Huang CJ, Hsu CH. Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial. BMC Complement Altern Med. 2018; 18:294–304.

16. Mitchell AE, Burns SA, Rudolf JL. Isozyme- and gender-specific induction of glutathione S-transferases by flavonoids. Arch Toxicol. 2007; 81:777–784.

17. Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, Cruz M, Rivas M, Cortez-Gomez B, Ceballos G, Villarreal F. Short- and long-term effects of (−)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2008; 295:H761–H767.

18. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006; 296:1255–1265.

19. Satoh E, Tohyama N, Nishimura M. Comparison of the antioxidant activity of roasted tea with green, oolong, and black teas. Int J Food Sci Nutr. 2005; 56:551–559.

20. Sands-Lincoln M, Loucks EB, Lu B, Carskadon MA, Sharkey K, Stefanick ML, Ockene J, Shah N, Hairston KG, Robinson JG, Limacher M, Hale L, Eaton CB. Sleep duration, insomnia, and coronary heart disease among postmenopausal women in the Women's Health Initiative. J Womens Health (Larchmt). 2013; 22:477–486.